LANXESS India helps to fight COVID 19 pandemic
April 2, 2020 6:34 pm
To help fight the current COVID-19 pandemic in India, specialty chemicals company LANXESS India has donated its highly effective Rely+On™ Virkon™ disinfectant to Thane Municipal Corporation (TMC) to reduce the cross contamination of COVID-19 in civic hospitals and other establishments.
Rely+On™ Virkon™ inactivates coronavirus quickly
With regard to the current global Coronavirus situation, independent tests have proven that Rely+On™ Virkon™ quickly inactivates a closely related surrogate of the currently spreading coronavirus strain. From these tests it can be concluded that Rely+On™ Virkon™ would also be effective against SARS-CoV-2 which is causing the current COVID-19 epidemic.
The independent test results indicated that Rely+On™ Virkon™ achieved inactivation of the coronavirus strain at a 1:100 dilution rate with a 10-minute contact time. This corresponds to test conditions required by the U.S. Environmental Protection Agency (EPA) and proves the performance and suitability of Rely+On™ Virkon™ for practical use.
Rely+On™ Virkon™ is diluted for application and sprayed on hard surfaces and equipment. It can therefore help to reduce the risk of cross contamination from surfaces, door handles, tables or chairs during disinfection measures at public transport terminals, airports, hospitals, clinics, shopping malls, etc.
Due to this wide application range, there has been a significant increase in demand from the Indian industry as many private hospitals and several corporations have placed significant orders of the disinfectant in their own efforts to limit the spread of the disease in their organisations.
Neelanjan Banerjee, Vice Chairman and Managing Director, LANXESS India commented, “We are working concertedly to ensure that our production and logistics capacities are optimally aligned to cater to the surge in demand for Rely+On Virkon. We are committed to fully utilise our product expertise to help fight the spread of COVID-19.”
Cookie Consent
We use cookies to personalize your experience. By continuing to visit this website you agree to our Terms & Conditions, Privacy Policy and Cookie Policy.